Platinum Industries Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Efficient capital deployment (ROCE 15.7%)
- ✓Attractively valued vs sector (P/E 24.1x vs industry 47.1x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SOLARINDS Solar Industries India Limited | ₹18,830 | ₹1.7L Cr | 99.6 | 27.13 | 31.5 | 36.8 | 0.17 |
| PIDILITIND Pidilite Industries Limited | ₹1,609 | ₹1.6L Cr | 64.7 | 15.18 | 23.9 | 31 | 0.05 |
| SRF SRF Limited | ₹2,818 | ₹85K Cr | 44.8 | 5.95 | 14.3 | 14.6 | 0.35 |
| LINDEINDIA Linde India Limited | ₹7,004 +0.11% | ₹61K Cr | 111 | 15.49 | 13.6 | 18.2 | 0.02 |
| COROMANDEL Coromandel International Limited | ₹2,054 +1.68% | ₹60K Cr | 30.9 | 4.12 | 16.4 | 22 | 0.11 |
| FACT Fertilizers and Chemicals Travancore Limited | ₹833 +0.26% | ₹54K Cr | 3,642 | 41 | 1.61 | 8.65 | 2.79 |
| UPL UPL Limited | ₹607 | ₹52K Cr | 27.5 | 1.48 | 5.91 | 10.2 | 0.94 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
PLATIND · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 71.00% | 71.00% | 71.00% | 71.00% | 71.00% | 71.00% |
| FII | 3.81% | 0.72% | 1.49% | 0.82% | 0.59% | 0.59% |
| DII | 2.68% | 3.04% | 2.68% | 2.68% | 2.79% | 2.95% |
| Public | 22.53% | 25.25% | 24.86% | 25.52% | 25.63% | 25.48% |
Latest News
All news →Platinum Industries sees spurt in trading volume
*Platinum Industries sees spurt in trading volume* — A significant surge in trading volume has been observed in Platinum Industries Limited. The NSE has queried the company as part of its surveillance mechanism to safeguard investor interests. The firm has submitted its response to the exchange. 📊 *STOCKS:* PLATINUM | 🏢 *SECTOR:* Trading | #LOWIMPACT #VolumeSurge
Glenmark advances Phase 3 trial for ovarian cancer drug
*Glenmark advances Phase 3 trial for ovarian cancer drug*. The company has progressed its multi-country Phase 3 clinical trial of Trastuzumab rezetecan in platinum-resistant ovarian cancer. This advancement signals positive momentum in its oncology pipeline. **Phase 3 trials** are pivotal for regulatory approval and market potential. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ClinicalTrial
Platinum Industries hosts analyst and investor meet
*Platinum Industries hosts analyst and investor meet.* The company conducted a plant visit as part of engagement with institutional investors. Such events help clarify business strategy and operations. No financial announcements or guidance changes were reported. 📊 *STOCKS:* PLATINUM | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #AnalystMeet